Akari Therapeutics Announces ADS Ratio Change
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) will change its American Depositary Share ratio from 1 ADS = 2,000 ordinary shares to 1 ADS = 80,000 ordinary shares, effective March 31, 2026. ADS holders must exchange every forty ADSs for one new ADS.
Deutsche Bank will arrange the exchange, no fractional new ADSs will be issued, and fractional entitlements will be aggregated, sold, and distributed in cash (net of fees). Akari said the change aims to help maintain Nasdaq minimum bid price compliance and cautioned it cannot assure post-change ADS price performance.
Positive
- Effective ratio change to 1 ADS = 80,000 ordinary shares
- Measure intended to maintain Nasdaq minimum bid price compliance
- Deutsche Bank to arrange ADS exchange process
Negative
- ADS price performance uncertain after the ratio change
- Fractional entitlements converted to cash after deduction of fees
Market Reaction – AKTX
Following this news, AKTX has declined 9.72%, reflecting a notable negative market reaction. Our momentum scanner has triggered 13 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.20. This price movement has removed approximately $1M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
AKTX fell 9.69% while key biotech peers showed modest, mixed moves (e.g., QTTB -2.7%, LIXT -1.63%, ALLR -2.34%). Only ALLR appeared in momentum scans, up 1.600000075995922%, suggesting today’s pressure is stock-specific to AKTX rather than a sector-wide biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | CEO strategic update | Positive | -10.7% | CEO Corner reviewed first-year progress and path toward clinical development. |
| Feb 26 | SAB appointment | Positive | -0.7% | Added cancer biology and RNA expert to Scientific Advisory Board for AKTX-101. |
| Feb 23 | SAB appointment | Positive | +2.7% | Appointed globally recognized RNA biology and cancer researcher to SAB. |
| Feb 18 | Conference presentation | Neutral | -1.6% | Announced CEO presentation at 2026 Biocom Global Partnering & Investor Conference. |
| Feb 11 | Investor interview | Positive | +1.4% | Virtual investor interview on expanded ADC pipeline and AKTX-101 plans. |
Recent Akari news, even when strategically positive, has often been followed by flat-to-negative price reactions, with only some management and pipeline updates aligning positively with share performance.
Over the last few months, Akari has focused on building its oncology ADC platform and visibility. A Feb 11, 2026 investor interview highlighted its expanded pipeline and lead candidate AKTX-101, followed by Scientific Advisory Board appointments on Feb 23 and Feb 26. A CEO Corner on Mar 13, 2026 outlined strategic progress toward clinical development. Despite these seemingly constructive updates, price reactions were often negative, framing today’s ADS ratio change against a backdrop of strategic advancement but weak share performance.
Regulatory & Risk Context
Akari has an active S-3 shelf registration dated Jul 29, 2025, noted as effective with 2 recorded 424B5 usages through Dec 17, 2025. Reported fields indicate remaining capacity and limited prior usage, which together suggest the company retains potential flexibility for future registered offerings under this shelf.
Market Pulse Summary
The stock is down -9.7% following this news. A negative reaction despite the mechanical nature of an ADS ratio change fits a pattern where structurally focused updates did not ease shareholder concerns. The stock previously declined after strategic communications such as the Mar 13, 2026 CEO Corner, and it continued to trade well below the 0.69 200-day MA. Investors may have viewed the action as a response to prolonged weakness, leaving sentiment fragile.
Key Terms
depositary bank financial
AI-generated analysis. Not financial advice.
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is expected to be effective on March 31, 2026.
The ratio change is intended to enable Akari to maintain compliance with the Nasdaq minimum bid price requirement for continued listing. On the effective date, each ADS holder will be required to exchange every forty ADSs for one new ADS. Deutsche Bank, the depositary bank, will arrange for the exchange of the current ADSs for the new ADSs. There is no change to Akari’s underlying ordinary shares, and Akari’s ADSs will continue to trade on the NASDAQ Capital Market under the symbol AKTX.
No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by Deutsche Bank.
Akari can give no assurances of the performance of the ADS price following the ratio change.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding statements related to the ratio change and expected effective date of the ratio change. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
What ADS ratio change did Akari Therapeutics (AKTX) announce on March 17, 2026?
How will the ADS exchange for AKTX holders be executed on March 31, 2026?
Will Akari Therapeutics (AKTX) change its Nasdaq listing symbol after the ADS ratio adjustment?
What should Akari ADS holders expect regarding fractional ADS entitlements from the AKTX ratio change?
Why is Akari Therapeutics (AKTX) changing its ADS ratio and is it permanent?
How might the ADS ratio change affect liquidity and price for AKTX shareholders?
